AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Sight Sciences Announces TearCare System Recognition in TFOS DEWS III Guidelines
ByAinvest
Tuesday, Sep 2, 2025 4:07 pm ET1min read
Sight Sciences' TearCare System has been recognized in the TFOS DEWS III report, a widely recognized standard in dry eye disease management. The system's clinical efficacy is highlighted in multiple published studies, including the SAHARA and OLYMPIA randomized controlled trials. The report validates TearCare's integral role in patient care and solidifies its position alongside recognized technologies in ocular surface disease.
Sight Sciences Inc. (NASDAQ: SGHT) has announced that its TearCare System has been included in the TFOS DEWS III report, a widely recognized standard in dry eye disease management. The inclusion signifies significant validation for TearCare's clinical efficacy in treating dry eye disease (DED) and meibomian gland disease (MGD).The DEWS III report, published in the American Journal of Ophthalmology, highlights multiple clinical studies supporting TearCare's effectiveness. The SAHARA trial demonstrated clinical superiority over Restasis in improving Tear Breakup Time and gland function, while the OLYMPIA trial showed significant improvement in DED symptoms, particularly in severe cases compared to LipiFlow.
Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences, stated, "For the first time, TearCare has been officially included in the TFOS DEWS III Management and Therapy Report. This powerful third-party validation highlights TearCare’s clinical relevance in treating meibomian gland disease (MGD) and solidifies our position alongside the most recognized technologies in ocular surface disease."
The recognition of the TearCare System as an interventional procedure within the DEWS III report underscores its clinical efficacy and integral role in patient care. The report itself is highly influential for clinicians refining treatment algorithms for dry eye.
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative, interventional solutions intended to transform care and improve patients’ lives. The TearCare System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD).
References:
[1] https://www.stocktitan.net/news/SGHT/sight-sciences-announces-recognition-of-the-tear-care-system-in-tfos-706yz1hgj3hy.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet